64067-99-8

Usage

Chemical Properties

Brown Solid

Uses

Different sources of media describe the Uses of 64067-99-8 differently. You can refer to the following data:
1. Anti-inflammatory agent
2. Anti-inflammatory agent.

InChI:InChI=1/C9H8ClN3O2/c1-2-15-9(14)6-5-13-8(11-6)4-3-7(10)12-13/h3-5H,2H2,1H3

Upstream product

• 5469-69-2 6-chloro-pyridazin-3-ylamine 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 907945-67-9 ethyl 6-(4-chlorophenyl)imidazo[1,2-b]pyridazine-2-carboxylate 
• 193743-93-0 6-chloroimidazolo[1,2-b]pyridazine-2-carboxamide 
• 14714-24-0 6-chloroimidazo[1,2-b]pyridazine-2-carboxylic acid 

Relevant academic research and scientific papers

Imidazopyridazine compound, modified amphiphilic functional molecule and application thereof

The invention provides an imidazopyridazine compound which is screened according to a DNA (Deoxyribose Nucleic Acid) encoding compound library and has better PD-L1 inhibitory activity, an amphiphilic functional molecule which can be connected with an aldo

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

INHIBITORS OF PROTEASE ACTIVATED RECEPTOR-2

The present invention relates generally to compounds capable of inhibiting Protease Activated Receptor-2 (PAR2), and uses thereof. More specifically, the present invention relates to inhibitors of PAR2, to their preparation, and to their use in the treatment of diseases and disorders mediated by PAR2 signaling.

A potent antagonist of protease-Activated receptor 2 that inhibits multiple signaling functions in human cancer cellss

Protease-activated receptor 2 (PAR2) is a cell surface protein linked to G-protein dependent and independent intracellular signaling pathways that produce a wide range of physiological responses, including those related to metabolism, inflammation, pain, and cancer. Certain proteases, peptides, and nonpeptides are known to potently activate PAR2. However, no effective potent PAR2 antagonists have been reported yet despite their anticipated therapeutic potential. This study investigates antagonism of key PAR2-dependent signaling properties and functions by the imidazopyridazine compound I-191 (4-(8-(tert-butyl)-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl)-3,3-dimethylpiperazin-2-one) in cancer cells. At nanomolar concentrations, I-191 inhibited PAR2 binding of and activation by structurally distinct PAR2 agonists (trypsin, peptide, nonpeptide) in a concentration-dependent manner in cells of the human colon adenocarcinoma grade II cell line (HT29). I-191 potently attenuated multiple PAR2-mediated intracellular signaling pathways leading to Ca21 release, extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation, Ras homologue gene family, member A (RhoA) activation, and inhibition of forskolin-induced cAMP accumulation. The mechanism of action of I-191 was investigated using binding and calcium mobilization studies in HT29 cells where I-191 was shown to be noncompetitive and a negative allosteric modulator of the agonist 2f-LIGRL-NH2. The compound alone did not activate these PAR2-mediated pathways, even at high micromolar concentrations, indicating no bias in these signaling properties. I-191 also potently inhibited PAR2-mediated downstream functional responses, including expression and secretion of inflammatory cytokines and cell apoptosis and migration, in human colon adenocarcinoma grade II cell line (HT29) and human breast adenocarcinoma cells (MDA-MB-231). These findings indicate that I-191 is a potent PAR2 antagonist that inhibits multiple PAR2-induced signaling pathways and functional responses. I-191 may be a valuable tool for characterizing PAR2 functions in cancer and in other cellular, physiological, and disease settings.

TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: -(CR3R3)2-5-, -(CR3R3)x-Y-(CR3R3)y-, -Y-(CR3R3)2-3-Y-, -CR3R3-Y-(CR3R3)2-Y-,-Y-(CR3R3)2-Y-CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed ar

IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS

The present invention relates to substituted imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pΙ3Κβ inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS

The present invention relates to heterocyclyl linked imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PI3Kβ inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Anti-tumor activity with acetylene derivatives

The present invention relates to an aromatic ring disubstituted acetylene derivative of formula I, a pharmaceutical composition comprising the compound, and a use of the compound and of the pharmaceutical composition in the treatment and/or prevention of tumors, where A, B, T, M, Ra, Rb, Rt, m, n, and p are as defined in the present document.

Research on heterocyclic compounds. XXXVIII. Synthesis and pharmacological activity of imidazo[1,2-b]pyridazine-2-carboxylic derivatives

A series of imidazo[1,2-b]pyridazine-2-carboxylic acids, esters and amides was synthesized and tested for antiinflammatory, analgesic and ulcerogenic activities. The ethyl esters were prepared by cyclocondensation of some 3-aminopyridazines with ethyl bromopyruvate, followed by hydrolysis or ammonolysis in order to obtain the corresponding acids and amides. The inhibitory activity on the carrageenaninduced edema in the rat paw and on writhes induced by acetic acid in mice was evaluated, as well as the ulcerogenic action on the rat gastric mucosa. The pharmacological activity was discussed in terms of structure-activity relationships. In particular, the analgestic activity shown by these carboxylic derivatives was compared with that found in other series of imidazo[1,2-b]pyridazine analogues previously examined.